Web of Science: 44 cites, Scopus: 59 cites, Google Scholar: cites,
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Hájek, R. (University Hospital Ostrava)
Masszi, T (St István and St László Hospital of Budapest)
Petrucci,M.T. (Sapienza Università di Roma)
Palumbo, A. (Università di Torino)
Rosiñol, L. (Hospital Clínic de Barcelona)
Nagler, A. (Chaim Sheba Medical Center (Israel))
Yong, K.L. (University College London Cancer Institute)
Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia)
Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky)
Pour, L (University Hospital Ostrava)
Dimopoulos, M.A. (National and Kapodistrian University of Athens)
Maisnar, V. (Charles University Teaching Hospital, Hradec Králové)
Rossi, D. (Amedeo Avogadro University of Eastern Piedmont)
Kasparu, H. (Hospital Elisabethinen Linz)
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium)
Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel)
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel)
Jenner, M. (Southampton General Hospital, Hampshire, UK)
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland)
Dávid, M. (University of Pécs, Hungary)
de la Rubia, J. (Hospital Universitario La Fe, València)
Drach, J. (Medical University of Vienna)
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary)
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland)
Leleu, X. (Hopital Huriez, CHRU, Lille, France)
Munder, M. (University Medicine Mainz, Germany)
Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy)
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria)
Rajangam, K. (Onyx Pharmaceuticals, Inc.)
Chang, Y.L. (Onyx Pharmaceuticals, Inc.)
San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA)
Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)

Data: 2017
Resum: This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib (10-min intravenous infusion; 20 mg/m2 on days 1 and 2 of cycle 1; 27 mg/m2 thereafter) or a control regimen of low-dose corticosteroids (84 mg of dexamethasone or equivalent corticosteroid) with optional cyclophosphamide (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred and fifteen patients were randomized to carfilzomib (n = 157) or control (n = 158). Both groups had a median of five prior regimens. In the control group, 95% of patients received cyclophosphamide. Median OS was 10. 2 (95% confidence interval (CI) 8. 4-14. 4) vs 10. 0 months (95% CI 7. 7-12. 0) with carfilzomib vs control (hazard ratio = 0. 975; 95% CI 0. 760-1. 249; P = 0. 4172). Progression-free survival was similar between groups; overall response rate was higher with carfilzomib (19. 1 vs 11. 4%). The most common grade ⩾3 adverse events were anemia (25. 5 vs 30. 7%), thrombocytopenia (24. 2 vs 22. 2%) and neutropenia (7. 6 vs 12. 4%) with arfilzomib vs control. Median OS for single-agent carfilzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Publicat a: Leukemia, Vol. 31 (2017) , p. 107-114

DOI: 10.1038/leu.2016.176
PMID: 27416912


8 p, 788.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-10-04, darrera modificació el 2020-02-08



   Favorit i Compartir